Discovery and Optimization of Small Molecule Drug Leads and Probes
Tuesday, March 5, 2024
12:00 pm - 1:00 pm
Join the UH Drug Discovery Institute for this hybrid event. A Zoom link will be emailed to registered attendees.
About the Event
John
Buolamwini’s
research
entails
multidisciplinary
drug
design
and
discovery
and
probe
development,
using
synthetic
medicinal
chemistry,
computer-aided
molecular
design,
as
well
as
biochemical,
molecular
biology,
and
experimental
therapeutics
methodologies.
Disease
areas
of
interest
are
ischemic
heart
disease,
cancer
and
HIV/AIDS,
and
Alzheimer’s
disease.
Recent
molecular
targets
include
MDM2
oncoprotein,
nucleoside
transporters
(hENTs/hCNTs),
organic
anion
transporters
(hOATs),
and
STAT3.
Buolamwini’s
research
has
been
funded
continuously
for
over
25
years
by
agencies
such
as
the
American
Heart
Association,
Alzheimer’s
Research
Association,
Alzheimer’s
Drug
Discovery
Foundation,
and
many
National
Institutes
of
Health
(NIH)
institutes,
namely,
NCI,
NIGMS,
NIAID,
NIA,
and
NHLBI,
through
various
grant
mechanisms
including
R15s,
R21s
and
RO1s,
and
STTR.
His
presentation
will
be
highlighting
past
and
recent
results.
About the Speaker
John Buolamwini, Ph.D., is chair of Pharmaceutical Sciences at Rosalind Franklin University. He has held faculty positions in the United States for the past 30 years, including the University of Mississippi and the University of Tennessee, where he served as the Vice Chair and Director of Graduate Programs of the Department of Pharmaceutical Sciences from 2012-2014.
- Location
- Health 2, Room 3084 and Online
- Cost
- Free
- Contact
- For more information, contact Nadine Peterson, DDI Coordinator